Member Login

              Click here if you forgot your password.

Current Events

Qualified Person Education Course Module A - Live Online Training

29/30 November 2023
Live Online

EQPA Members Area

IMP Working Group Members Area

Document and track your personal development - with the Continuous Professional Development (CPD) Documentation Template

To access the template for documenting and tracking your past and ongoing activities, please go here.

After filling out the form, you will be able to create and print out a PDF file.

Labeling Requirements for IMPs Amended


Following a 1-month feedback period on the draft published in June this year the European Commission (EC) finally adopted on 6 September the revised Annex VI to Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR) as regards labelling requirements for IMPs. The Regulation will enter into force on the twentieth day following its publication in the Official Journal of the European Union and will be binding and directly applicable in all Member States.


The Commission Delegated Regulation amending the CTR as regards labelling requirements for unauthorized investigational (IMPs) and unauthorized auxiliary medicinal products (AxMPs) eliminates the obligation to include an expiry date on the primary packaging of IMPs / AxMPs in specific circumstances.

Feedback received from business organizations and companies on the draft delegated regulation, supported in majority the proposed rules. Some of these contributors proposed additional labelling exemptions, which were not considered due to the potential safety impact on clinical trial participants. Contributions were also received from citizens, who expressed their concerns. These concerns were mainly due to misunderstandings about the proposed rules, which were often understood as exemptions to label the expiry date for medicines or allowing unauthorized medicines to be put on the market. As a consequence, the draft Regulation was not amended after consultation.

The final Delegated Regulation and its Annex can be downloaded from the Commission's website, where the comments (including comments from EQPA's IMP Working Group) are also available. 

More information is provided under Unauthorised medicinal products used in clinical trials (labelling rules).


Conference Recommendations